Advice
Following a full submission
infliximab (Remicade®) is accepted for use within NHS Scotland for the treatment of severe, active Crohn's disease, in paediatric patients aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary nutrition therapy; or who are intolerant to or have contraindications for such therapies.
In an open label study 88% of patients had a clinical response following the induction regimen and this was maintained at one year in significantly more patients receiving infliximab every 8 weeks compared with every 12 weeks.
Download detailed advice111KB (PDF)
Medicine details
- Medicine name:
- infliximab (Remicade)
- SMC ID:
- 448/08
- Indication:
- Treatment of severe, active Crohn' s disease in paediatric patients
- Pharmaceutical company
- Schering-Plough Ltd
- BNF chapter
- Gastro-intestinal system
- Submission type
- Full
- Status
- Superseded
- Date advice published
- 10 March 2008